SIMPONI ARIA® (golimumab) for RA, PsA, and AS

SIMPONI ARIA^® IS THE ONLY FULLY HUMAN IV ANTI-TNFα APPROVED TO TREAT:

RA

Adult Patients with
Moderately to Severely
Active Rheumatoid Arthritis

PsA

ACTIVE PSORIATIC ARTHRITIS IN PATIENTS 2 YEARS AND OLDER

AS

ADULT PATIENTS WITH ACTIVE
ANKYLOSING SPONDYLITIS

pJIA ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
IN PATIENTS 2 YEARS AND OLDER

Dosing Calculator
FOR ADULT PATIENTS

Calculate a patient’s dose of
SIMPONI ARIA® based on weight

FIRST-LINE BIOLOGIC
COMMERCIAL COVERAGE¹^*

Under the medical benefit with no subcutaneous step therapy

Coverage rate is for rheumatoid arthritis and psoriatic arthritis only.

^*These percentages may not represent 100% of formulary lives due to data limitations.
Source: 1. Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of June 2022.

Medical Information Center

Last Updated October 2022

No footer links content fetched

RA

PsA

AS

Dosing CalculatorFOR ADULT PATIENTS

FIRST-LINE BIOLOGICCOMMERCIAL COVERAGE1*

Dosing Calculator
FOR ADULT PATIENTS

FIRST-LINE BIOLOGIC
COMMERCIAL COVERAGE¹^*